Syndax Pharmaceuticals SNDX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's operating cash flow?
- Syndax Pharmaceuticals (SNDX) reported operating cash flow of -$50.35M in Q1 2026.
- How has Syndax Pharmaceuticals's operating cash flow changed year-over-year?
- Syndax Pharmaceuticals's operating cash flow increased by 47.1% year-over-year, from -$95.16M to -$50.35M.
- What is the long-term trend for Syndax Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's operating cash flow has grown at a 82.5% compound annual growth rate (CAGR), from $29.13M to -$322.98M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.